• 1. Synthetic approaches toward sesterterpenoids
  Daniel T. Hog,Robert Webster,Dirk Trauner Nat. Prod. Rep. 2012 29 752
• 2. Therapeutic vulnerabilities of cancer stem cells and effects of natural products
  Keighley N. Reisenauer,Jaquelin Aroujo,Yongfeng Tao,Santhalakshmi Ranganathan,Daniel Romo,Joseph H. Taube Nat. Prod. Rep. 2023 40 1432
• 3. Recent updates on the bioactive compounds of the marine-derived genus Aspergillus
  Raha Orfali,Mahmoud A. Aboseada,Nada M. Abdel-Wahab,Hossam M. Hassan,Shagufta Perveen,Fuad Ameen,Eman Alturki,Usama Ramadan Abdelmohsen RSC Adv. 2021 11 17116
• 4. Hot off the press
  Robert A. Hill,Andrew Sutherland Nat. Prod. Rep. 2016 33 915
• 5. Engineering fungal terpene biosynthesis
  Zhiyong Yin,Jeroen S. Dickschat Nat. Prod. Rep. 2023 40 28

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Ophiobolane sesterterpenoids
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Sesterterpenoids Ophiobolane sesterterpenoids

Introduction to Ophiobolin C (CAS No. 19022-51-6)

Ophiobolin C, a naturally occurring compound with the chemical formula C₂₀H₁₆O₅, is a member of the ophiobolin family, which has garnered significant attention in the field of pharmaceutical and biochemical research. Its unique structural features and biological activities have positioned it as a subject of intense study, particularly for its potential therapeutic applications. This compound is primarily derived from the plant Ophiopogon japonicus, commonly known as mondo grass or lilyturf, and has been the focus of numerous investigations due to its distinct chemical profile and pharmacological properties.

The CAS No. 19022-51-6 assigned to Ophiobolin C underscores its identity as a well-characterized chemical entity in scientific literature. This numbering system ensures precise identification and differentiation from other compounds, facilitating accurate documentation and communication in research and industrial settings. The compound’s molecular structure, characterized by a fused ring system with hydroxyl and carbonyl functional groups, contributes to its remarkable reactivity and interaction with biological targets.

Recent advancements in biochemical research have highlighted the multifaceted biological activities of Ophiobolin C. Studies have demonstrated its potent antioxidant properties, which are attributed to its ability to scavenge free radicals and modulate oxidative stress pathways. This makes it a promising candidate for therapeutic interventions in conditions where oxidative damage plays a significant role, such as neurodegenerative diseases and chronic inflammation.

In addition to its antioxidant effects, Ophiobolin C has shown notable anti-inflammatory properties. Research indicates that it can inhibit the production of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), by modulating signaling pathways like NF-κB. These findings suggest that Ophiobolin C may have therapeutic potential in managing inflammatory disorders, including rheumatoid arthritis and inflammatory bowel disease.

Emerging evidence also suggests that Ophiobolin C exhibits cytotoxic effects against certain cancer cell lines. Its ability to induce apoptosis in malignant cells while sparing healthy cells has attracted considerable interest in oncology research. Mechanistic studies have revealed that Ophiobolin C can disrupt mitochondrial function and activate caspase-dependent apoptosis pathways in cancer cells. These properties make it a compelling candidate for further development as an anticancer agent.

The structural complexity of Ophiobolin C presents both challenges and opportunities for synthetic chemistry. Researchers have been exploring various synthetic routes to optimize its production and modify its pharmacological profile. Advances in synthetic methodologies have enabled the development of semi-synthetic derivatives with enhanced bioavailability and targeted activity. These derivatives hold promise for improving the therapeutic efficacy of Ophiobolin C while minimizing potential side effects.

The pharmacokinetic properties of Ophiobolin C are another area of active investigation. Studies have examined its absorption, distribution, metabolism, and excretion (ADME) profiles to better understand how it interacts with biological systems. While initial findings suggest that Ophiobolin C has moderate bioavailability, ongoing research aims to enhance these parameters through structural modifications. Such improvements are crucial for translating preclinical findings into effective clinical applications.

In conclusion, Ophiobolin C (CAS No. 19022-51-6) represents a fascinating compound with diverse biological activities that warrant further exploration. Its antioxidant, anti-inflammatory, and anticancer properties make it a promising candidate for therapeutic development in various medical fields. As research continues to uncover new insights into its mechanisms of action and pharmacological effects, Ophiobolin C is poised to play an increasingly significant role in pharmaceutical innovation.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)